Publication: Kolinesteraz 3 homolog inhibritörlerine direnç geni rs1528133 polimorfizminin yeme alışkanlığı ve şişmanlık ile ilişkisi
Abstract
KOLİNESTERAZ 3 HOMOLOG İNHİBİTÖRLERİNE DİRENÇ GENİ rs1528133 POLİMORFİZMİNİN YEME ALIŞKANLIĞI VE ŞİŞMANLIK İLE İLİŞKİSİ Bu çalışmada, RIC-3 geni rs1528133 polimorfizminin şişman ve şişman olmayan kontrol bireylerdeki allel sıklıklarının saptanması, rs1528133 genotiplerinin antropometrik, diyabet ve şişmanlık ile ilişkili parametreler üzerindeki etkilerinin belirlenmesi, lojistik regresyon analizi ile de şişmanlık risk faktörlerinin araştırılması, RIC-3 geni rs11528133 genotiplerinin beslenme alışkanlıklarının belirlenmesi üzerindeki nutrigenomik etkilerin araştırılması ve hipertansiyon/ tip 2 diyabet/ koroner arter hastalığı tedavisinde kullanılan ilaçlarla olan etkileşimlerinin saptanarak, toplumumuza özgü farmakogenomik verilerin belirlenmesi amaçlanmıştır. Çalışma, şişmanlık tanısı konmuş 85 şişman ve 41 şişman olmayan bireyde yapıldı. RIC-3 geni rs1528133 genotipleri qPZR yöntemi ile saptandı. RIC-3 geni rs1528133 genotip sıklıkları şişmanlarda, homozigot yabanil tip (A/ A), heterozigot (A/ C) genotipler için sırasıyla %89.4, %10.6 ve şişman olmayan grupta ise %92.7, %7.3 olarak tespit edildi. Çalışma gruplarımızda polimorfik (C/ C) genotipli birey saptanmadı. Genotip sıklıkları çalışma grupları arasında farklı bulunmadı. Çalışmamızda, rs1528133 heterozigot genotipindeki kişilerin (%16.7) yabanil tipte genotiptekilere kıyasla (%46.9) daha düşük sıklıkta antihipertansif ilaç kullandığı saptandı. RIC-3 geni rs1528133 heterozigot genotipe sahip olan bireylerin, homozigot yabanil tip genotipe sahip kişilere oranla yüksek glisemik yüke sahip, yağdan ve proteinden zengin beslenme alışkanlıkları olduğu belirlendi. RIC-3 geni rs1528133 genotipini heterozigot olarak taşıyanlarda anjiyotensin dönüştürücü enzim inhibitörü, beta-bloker ve asetilsalisilik asitten başka alternatif antihipertansif ilaçların etkilerinin araştırılması gerekliliğini ortaya koymaktadır.
RELATIONSHIP OF RESİSTANT TO İNHİBİTORS OF CHOLİNESTERASE-3 rs1528133 POLYMORPHISM WITH EATING HABITS AND OBESITY The aim of this study was to determine the allele frequencies of RIC-3 gene rs1528133 polymorphism in obese and non-obese control subjects, to detect the effects of rs1528133 genotypes on antropometric, diabetes and obesity related parameters, to search for obesity risk factors with logistic regression analysis, to understand the effects of RIC-3 gene rs11528133 genotypes on eating habits and with drugs used in hypertension/ type 2 diabetes/ coronary artery disease treatment, and thus to detect nutrigenomic and pharmacogenomic data specific for our population. The study was performed on 85 obese and 41 non-obese conrol subjects. RIC-3 gene rs1528133 genotypes were determined with qPCR method. The RIC-3 gene rs1528133 genotype frequencies and were determined respectively as %89.4 for homozygous wild type (A/ A), %10.6 for heterozygous (A/ C) in obese and %92.7 for A/ A, %7.3 for A/ C in non-obese patients. The polymorphic genotype (C/ C) was not detected in our study group. Genotype frequencies were not found to differ among study groups. The percentage of rs1528133 heterozygous individuals (16.7%) using antihypertensive drugs were lower in comparison to wild type genotype carriers (46.9%). Individuals heterozygous for the RIC-3 gene rs1528133 variation were found to have eating habits prefering higher glycemic load, fat and protein rich diet compared to homozygous wild type genotype carriers. Alternative antihpertensive drugs and their effects are needed to be explored other than angiotensin converting enzyme inhibitor, beta-blocker and acetylsalicylic acid.
RELATIONSHIP OF RESİSTANT TO İNHİBİTORS OF CHOLİNESTERASE-3 rs1528133 POLYMORPHISM WITH EATING HABITS AND OBESITY The aim of this study was to determine the allele frequencies of RIC-3 gene rs1528133 polymorphism in obese and non-obese control subjects, to detect the effects of rs1528133 genotypes on antropometric, diabetes and obesity related parameters, to search for obesity risk factors with logistic regression analysis, to understand the effects of RIC-3 gene rs11528133 genotypes on eating habits and with drugs used in hypertension/ type 2 diabetes/ coronary artery disease treatment, and thus to detect nutrigenomic and pharmacogenomic data specific for our population. The study was performed on 85 obese and 41 non-obese conrol subjects. RIC-3 gene rs1528133 genotypes were determined with qPCR method. The RIC-3 gene rs1528133 genotype frequencies and were determined respectively as %89.4 for homozygous wild type (A/ A), %10.6 for heterozygous (A/ C) in obese and %92.7 for A/ A, %7.3 for A/ C in non-obese patients. The polymorphic genotype (C/ C) was not detected in our study group. Genotype frequencies were not found to differ among study groups. The percentage of rs1528133 heterozygous individuals (16.7%) using antihypertensive drugs were lower in comparison to wild type genotype carriers (46.9%). Individuals heterozygous for the RIC-3 gene rs1528133 variation were found to have eating habits prefering higher glycemic load, fat and protein rich diet compared to homozygous wild type genotype carriers. Alternative antihpertensive drugs and their effects are needed to be explored other than angiotensin converting enzyme inhibitor, beta-blocker and acetylsalicylic acid.